It was predicted that the pharmaceutical and bio sectors would continue their unstable trend in the second half. It has emerged as the biggest challenge for small and medium-sized enterprises (SMEs) to withstand the harsh cold weather of the financial crisis through strong cost control. In the second half of the year, if interest rates peak and good results are achieved in promising fields such as Alzheimer's disease, ADC, and cell genes, it is predicted that the lost fighting spirit will be restored.


Park Byeong-guk, a researcher at NH Investment & Securities, said at the '2nd Daily Family Day' held by Daily Partners, a bio-specialized venture capital (VC), on the 26th, "In 2021 and 2022, the pharm